Vaerl.phi.se, Denmark

Jphirgen Drejer


Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1991

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Jphirgen Drejer in Heterocyclic Compounds

Introduction

Jphirgen Drejer, an accomplished inventor based in Vaerl.phi.se, Denmark, has made significant contributions to the field of heterocyclic chemistry. With one patent to his name, Drejer’s work reflects a dedication to innovation and the advancement of chemical compounds, particularly in relation to thiazoloquinoxalines.

Latest Patents

Drejer's notable patent focuses on thiazoloquinoxalines, specifically concerning heterocyclic dihydroxyquinoxaline compounds characterized by the formula ##STR1##. This invention encompasses a series of compounds where R² can be hydrogen, NO₂, NH₂, CN, halogen, or SO₂NH₂, showcasing a diverse range of potential applications in various industries.

Career Highlights

Currently, Jphirgen Drejer is associated with Novo Nordisk A/S, a leading global healthcare company that specializes in diabetes care and biopharmaceuticals. His work within the company emphasizes the intersection of innovative research and practical applications in the pharmaceutical field, contributing to the advancement of health solutions worldwide.

Collaborations

Throughout his career, Jphirgen Drejer has worked alongside esteemed colleagues such as Poul Jacobsen and Flemming E. Nielsen. These collaborations highlight the importance of teamwork in driving innovation and achieving breakthroughs in scientific research.

Conclusion

With a focus on the development of heterocyclic compounds, Jphirgen Drejer stands as a noteworthy figure in the realm of chemical innovation. His contributions not only reflect his ingenuity as an inventor but also pave the way for advancements in health care and pharmaceutical products.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…